Lysyl-Tyrosyl-Lysine Acetate

Lysyl-Tyrosyl-Lysine Acetate

SCHEMBL4291040

CC(=O)O.NCCCCC(N)C(=O)NC(Cc1ccc(O)cc1)C(=O)NC(CCCCN)C(=O)O

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Lysyl-Tyrosyl-Lysine Acetate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
NPY4R P50391 5/20 0.61
NPY1R P25929 4/20 0.61
NPY2R P49146 3/20 0.61
LNPEP Q9UIQ6 2/20 0.57
ERAP2 Q6P179 1/20 0.57
NPY5R Q15761 2/20 0.54
NTSR2 O95665 2/20 0.53
NTSR1 P30989 2/20 0.53
GNPAT O15228 1/20 0.52
OPRD1 P41143 3/20 0.51
ENPEP Q07075 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lysyl-Tyrosyl-Lysine Acetate SCHEMBL6275111 0.97 NPY4R (0.62) NPY4RNPY1RNPY2RLNPEPERAP2
Lysyl-Tyrosyl-Lysine Acetate SCHEMBL6275116 0.97 NPY4R (0.62) NPY4RNPY1RNPY2RLNPEPERAP2
SCHEMBL27942027 0.97 NPY4R (0.62) NPY4RNPY1RNPY2RLNPEPERAP2
SCHEMBL30851358 0.95 NPY4R (0.63) NPY4RNPY1RNPY2RLNPEPERAP2
Acetic Acid SCHEMBL28326516 0.94 NPY4R (0.59) NPY4RNPY1RNPY2RLNPEPERAP2
Acetic Acid SCHEMBL20489334 0.94 NPY4R (0.59) NPY4RNPY1RNPY2RLNPEPERAP2
SCHEMBL30523264 0.94 LNPEP (0.63) NPY4RNPY1RNPY2RLNPEPERAP2
SCHEMBL29577087 0.93 NPY4R (0.59) NPY4RNPY1RNPY2RLNPEPERAP2
SCHEMBL29576811 0.93 NPY4R (0.59) NPY4RNPY1RNPY2RLNPEPERAP2
SCHEMBL30931517 0.93 LNPEP (0.62) NPY4RNPY1RNPY2RLNPEPERAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143279-A1 Methods and compositions for treating metabolic disorders PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2009-06-04 US disclosed
WO-2008156654-A2 CYTOSKELETON MODULATORS FOR TREATING METABOLIC DISORDERS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143279-A1 Methods and compositions for treating metabolic disorders PC, PCK2, CS NPY4R 1672/4885NPY1R 2267/4885NPY2R 2027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.